SS
ORPH

Steve Schonfeld’s Orphazyme A/S ORPH Stock Holding History

Steve Schonfeld’s Portfolio ORPH Stock Details ORPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,200
Closed -$63K – 2789
2021
Q3 		$63K Buy
+15,200
New +$78.2K ﹤0.01% 1984
2020
Q4 		– Sell
-149,500
Closed -$1.54M – 1991
2020
Q3 		$1.54M Buy
+149,500
New +$1.5M 0.03% 587

Other funds holding ORPH

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $3.64B AUM 83.38% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Steve Schonfeld's ORPH Position: Q4 2021 in Review

Steve Schonfeld sold out of Orphazyme A/S (ORPH) in Q4 2021, closing a stake of 15,200 shares — an estimated $63K sold.

Steve Schonfeld first reported a position in ORPH in Q3 2020 and held it in 2 quarters. The position peaked at $1.54M in Q3 2020. 20 funds tracked by Wall St. Rank hold ORPH as of Q4 2021.

  • Steve Schonfeld reported no remaining Orphazyme A/S position as of Q4 2021 after selling out during the quarter.
  • Steve Schonfeld sold 15,200 Orphazyme A/S shares in Q4 2021, an estimated $63K.
  • Steve Schonfeld first reported a position in Orphazyme A/S in Q3 2020 and held it in 2 quarters.
  • Steve Schonfeld's Orphazyme A/S position peaked at $1.54M in Q3 2020.
  • 20 funds tracked by Wall St. Rank held Orphazyme A/S as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.